Article Text

Download PDFPDF

Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation
  1. A De Soyza1,
  2. K Morris2,
  3. A McDowell4,
  4. C Doherty3,
  5. L Archer2,
  6. J Perry2,
  7. J R W Govan3,
  8. P A Corris1,
  9. K Gould2
  1. 1Transplantation and Immunobiology Group, The Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK
  2. 2Department of Medical Microbiology, The Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK
  3. 3Department of Medical Microbiology, University of Edinburgh, Edinburgh EH8 9AG, UK
  4. 4Biomolecular Sciences Group, School of Pharmacy, Queen’s University, Belfast BT9 7BL, UK
  1. Correspondence to:
    Dr A De Soyza
    William Leech Centre, The Freeman Hospital, High Heaton, Newcastle upon Tyne NE7 7DN, UK; anthony.de-soyzancl.ac.uk

Abstract

Background: It has previously been reported that patients infected with Burkholderia cenocepacia (genomovar III) before lung transplantation have a poorer outcome than those with other B cepacia complex infections.

Methods: An extensive study was conducted to determine the prevalence and clonality of B cepacia complex genomovars isolated from patients referred for transplant assessment between 1989 to the present and, where appropriate, whether strain type was related to transplant outcome.

Results: Isolates from 29 patients were identified as B cepacia complex organisms by molecular analysis. Thirteen patients (45%) were infected with the highly transmissible ET-12 strain of B cenocepacia recA lineage III-A, while all remaining patients were infected with genetically unique B cenocepacia, B multivorans, and B vietnamiensis strains. All previously reported deaths following transplantation were associated with ET-12 infection.

Conclusions: The ET-12 strain is the predominant cause of B cenocepacia infections in patients with cystic fibrosis referred to our pulmonary transplant centre and is associated with poor transplant outcomes using standard treatment regimens.

  • Burkholderia cepacia complex
  • lung transplantation
  • cystic fibrosis
  • clonality
View Full Text

Statistics from Altmetric.com

Footnotes

  • Dr De Soyza received support via Breathe North and Wellcome Trust Clinical training fellowships.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.